Cargando…
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactiv...
Autores principales: | Wang, Hui, Zhang, Yuntao, Huang, Baoying, Deng, Wei, Quan, Yaru, Wang, Wenling, Xu, Wenbo, Zhao, Yuxiu, Li, Na, Zhang, Jin, Liang, Hongyang, Bao, Linlin, Xu, Yanfeng, Ding, Ling, Zhou, Weimin, Gao, Hong, Liu, Jiangning, Niu, Peihua, Zhao, Li, Zhen, Wei, Fu, Hui, Yu, Shouzhi, Zhang, Zhengli, Xu, Guangxue, Li, Changgui, Lou, Zhiyong, Xu, Miao, Qin, Chuan, Wu, Guizhen, Gao, George Fu, Tan, Wenjie, Yang, Xiaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275151/ https://www.ncbi.nlm.nih.gov/pubmed/32778225 http://dx.doi.org/10.1016/j.cell.2020.06.008 |
Ejemplares similares
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021) -
BBIBP-CorV: Hepatitis: case report
Publicado: (2022) -
BBIBP-CorV: Anterior uveitis: case report
Publicado: (2022) -
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
por: Xia, ShengLi, et al.
Publicado: (2022) -
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
por: Zhang, Yaowen, et al.
Publicado: (2022)